Today: 10 June 2026
Silver price breaks $100: what’s driving XAG/USD — and what could knock it back
23 January 2026
2 mins read

Silver price breaks $100: what’s driving XAG/USD — and what could knock it back

New York, January 23, 2026, 13:46 ET — Regular session underway.

  • Silver hovered near $101 an ounce on Friday, climbing roughly 5% during the session.
  • Precious metals remained under the spotlight amid ongoing geopolitical tensions and steady safe-haven buying in wider markets.
  • Traders are focused on the Fed meeting set for Jan. 27-28, with the press conference coming Jan. 28.

Spot silver (XAG/USD) shot past $100 an ounce on Friday, last trading 5.1% higher at $101. Gold meanwhile climbed to a record $4,988. Silver has jumped roughly 40% in 2026 after soaring 147% last year, while the gold-to-silver ratio shrank to about 50 from 105 in April. StoneX analyst Rhona O’Connell called it “a self-propelled frenzy.” Reuters

Hitting the $100 mark is a big deal, given silver’s notorious volatility. Breaking that key threshold can trigger momentum buying and prompt shorts to cover fast. MarketWatch reported silver briefly reached $100.78 and “closed” at $100.64, up over 42% this month—its best rally since late 1979. “Short-term supply constraints are a critical driver,” noted Fawad Razaqzada at Forex.com. MarketWatch

The broader precious-metals complex was already firing on all cylinders when gold surged beyond $4,900 an ounce Thursday. The dollar’s retreat helped fuel the rally, alongside bets that the Federal Reserve will ease policy later this year. Nikos Tzabouras, senior market analyst at Tradu, noted that “silver has a far more compelling fundamental narrative than gold.” Reuters

Inflation figures have kept the rate-cut narrative in play. Core PCE inflation — the Fed’s favored measure — came in at 2.8% year-on-year for November, in line with expectations and slightly above the prior 2.7%, per Investing.com’s calendar. The BEA is set to release the next PCE data on Feb. 20.

Silver’s rally is making waves in proxy plays as well. The iShares Silver Trust (SLV), an ETF backed by physical silver and traded like a stock, climbed roughly 5.2% to $91.66 in U.S. trading. iShares reported holdings of 16,104.08 tonnes in the trust as of Jan. 22.

Futures followed the spot price climb, with Investing.com data showing silver futures rising roughly 4.8% during the session. Prices fluctuated between about $96.70 and just over $101.10. Spot prices, which represent immediate delivery, can differ from futures—contracts settled later—especially when market positioning tightens.

The bigger picture pushed things further. According to a Financial Times report, gold is on track for its strongest week since 2008, shaken by the Greenland standoff’s impact on the dollar. That turmoil also helped silver break past $100. The report noted the dollar index slid roughly 1.7% over the week.

Silver’s gains come with a catch: the higher it climbs, the more vulnerable it becomes. BofA strategist Michael Widmer pegged a “fundamentally justified” silver price near $60 but cautioned that industrial demand might weaken at that level. BNP Paribas strategist David Wilson flagged the risk of profit-taking kicking in “sooner rather than later,” especially if the squeeze on physical supply starts to ease. Investing.com

The Fed takes center stage next. The Jan. 27-28 meeting will drive moves in rates and the dollar, with traders dissecting the statement and the Chair’s tone for clues on whether easing is near—or still off the table.

Stock Market Today

  • Cencora Partners with Kite Pharma Boosting CAR T Therapy Distribution and Highlighting Undervalued Shares
    June 10, 2026, 10:31 AM EDT. Cencora (NYSE:COR) has inked a key U.S. distribution deal with Kite Pharma, a Gilead company, to facilitate access for FDA-approved CAR T cell therapies, a type of personalized cancer treatment. The partnership aims to streamline logistics for treatment centers, enhancing Cencora's role in complex therapy distribution. Despite a mixed recent share price with a 17.5% decline year-to-date, shares trade at $279.57, about 25% below analysts' $350.58 target and 42.6% under Simply Wall St's fair value estimate, indicating undervaluation. The deal may reshape market views on Cencora's growth in next-generation treatment logistics. Investors should monitor CAR T therapy volumes, new center activations, and financial leverage amid capital needs.

Latest articles

HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week
Previous Story

HBAN stock slips as Huntington tees up new debt sale ahead of Cadence deal — what to watch next week

Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision
Next Story

Broadcom stock slides as Intel shock ripples through chips ahead of Fed decision

Go toTop